Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2137122 | Leukemia Research | 2012 | 9 Pages |
Abstract
Our retrospective analysis explored the role of leukemia cutis (LC) in disease progression of chronic myelomonocytic leukemia (CMML). Of 108 patients with CMML, 11 patients (10.2%) had LC including its equivalent (2 patients). Four of these patients developed acute myeloid leukemia (AML) within 0–4 months. The remaining 7 patients demonstrated increased monocytes (<20% blasts), with 3 demonstrating extramedullary involvement. Overall survival from LC to disease progression was 7.8 months. Overall survival from diagnosis to the last follow-up in patients with LC was 28.2 months, shorter than patients without LC (44 months). LC and its equivalent could predict disease progression to AML.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Rahel A. Mathew, John M. Bennett, Jane Jijun Liu, Rami S. Komrokji, Jeffrey E. Lancet, Mojdeh Naghashpour, Jane L. Messina, Alan F. List, Lynn C. Moscinski, Ling Zhang,